Device Trial Radar · NCT04566055
Assessing AlloSure Dd-cfDNA Monitoring Insights of Renal Allografts With Longitudinal Surveillance
Last checked: Nov 20, 2026Latest source record: Oct 5, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,000
Actual
Start
Mar 1, 2019
Primary completion
Oct 1, 2020
Study completion Oct 1, 2020
Sponsor
- Lead sponsor
- CareDxNot on our public-company list
- Sponsor type
- Industry
- First posted
- Sep 28, 2020
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Prospective Observational Multicenter Cohort. External validation of donor derived cell free DNA in Renal Transplantation. Assessing performance of dd-cfDNA as a surveillance tool and its association with clinical outcomes. Outcomes include formation of de-novo DSA, eGFR decline, performance of AlloSure dd-cfDNA in Allograft rejection.
Conditions
- Kidney Transplant Rejection
Interventions
AlloSureDevice
Patients will receive donor-derived cell-free DNA testing for surveillance and for-cause.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Validation of AlloSure in Allograft rejectionTime frame: October 2020
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
University of Colorado Hospital
Aurora, Colorado
Tampa General Hosptial
Tampa, Florida
University of Maryland
Baltimore, Maryland
5 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.